No Data
No Data
NKGen Biotech Awards Stock Options to Executives
NKGen Biotech Receives Nasdaq Non-Compliance Notice For Market Value Of Publicly Held Shares Below $15M Minimum, Plans To Monitor And Explore Options To Regain Compliance
NKGen Biotech Secures Key Role in NKMax Deal
NKGen Biotech Selected As Stalking Horse Bidder For NKMax; NKGen Proposal Included Up To $18M In Committed Funding.
Express News | NKGen Biotech: Selected as Preferred Stalking Horse Bidder for Nkmax Co., in Nkmax's Court-Managed Rehabilitation Process in South Korea
Express News | NKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings Panel